Direct-to-consumer genetic testing company 23andMe is buying CureTogether, a forum for patient-reported ratings of drugs and other treatments that aims to suggest new areas for research. Terms of the deal, 23andMe’s first acquisition, were not disclosed.

CureTogether’s database includes more than 4 million data points across more than 500 health conditions. 23andMe believes that data could help inform future genetic discoveries and will complement its own research-focused data gathering efforts.

Alexandra Carmichael, co-founder of CureTogether, says she sees an opportunity for members of her site to “help accelerate research discoveries enabled by this unprecedented compilation of community-contributed genetic and phenotypic data.”

The $299 Personal Genome Service offered by 23andMe provides customers more than 200 health and traits reports as well as genetic ancestry information. The service has proved popular among people eager to learn more about their genetic information through DNA analysis. But the company’s plans to leverage customers’ data to conduct research into the genetic basis of disease hit turbulence in May, when it announced its first patent on a gene variant related to Parkinson’s disease. Despite consenting to allow their data to be used to support such research, some customers expressed concern and criticism over any gene patents derived from their genetic information.

For now, the companies hope that CureTogether’s forum for allowing customers to share quantitative information on medical conditions, talk about sensitive symptoms and compare which treatments work best for them as they track their health will be complementary, and help extend work the company has already done in helping gather data on Parkinson’s disease, sarcoma, and bone marrow diseases.